A daily pill could be just as effective at lowering blood sugar and aiding weight loss in people with type 2 diabetes as the popular injectables Mounjaro and Ozempic.
That's according to the results of a clinical trial announced by US pharmaceutical company Eli Lilly, the New York Times reports.
The drug, orforgliprone, is a GLP-1, a class of drugs that have become blockbusters for their weight loss effects.
However, GLP-1s are expensive, must be refrigerated and injected.
A pill that gives similar results has the potential to become much more widely used.
"In the coming decades, 700 million people worldwide will have type 2 diabetes and over a billion will be obese. Injections cannot be the solution for billions of people around the world," says Dr. Daniel Skowronski, Eli Lilly's chief scientific officer. | BGNES
